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Summary
A comprehensive study of global phosphorylation
events in biological systems is critical. We report
a chemistry-based capture-release-tag method for
isolation of complex phospho-Ser/Thr-containing pep-
tides by liquid -elimination combined with solid-
phase Michael addition. The free thiol groups of
6-(mercapto-acetylamino)-hexanoic acid functional-
ized resin are used as immobilized Michael donors to
capture dehydro-serine/threonine peptides. After an
acid-mediated release step, phospho-peptides are la-
beled with a 6-(2-mercapto-acetylamine)-hexanoic
amide tag at phosphorylated sites. We applied this
method to analyze the phosphorylation status of
microtubule-associated proteins. We find that a CDK5
substrate microtubule-associated protein 2 (MAP2) is
phosphorylated on residues that are within a homolo-
gous region of Tau. The chemical method corrobo-
rates previous results and suggests that Tau and
MAP2 may contain a CDK5 phosphorylation motif.
Introduction
In the postgenomic era, functional proteomics will ac-
celerate the understanding of complicated biological
pathways regulated by enzymatic activities [1]. Protein
phosphorylation/dephosphorylation catalyzed by pro-
tein kinases/phosphatases is essential in a variety of
signaling processes [2, 3]. However, methods for en-
riching phosphorylated epitopes from cells or tissues
remain to be improved [4].
β-elimination of phosphates on serine and threonine
residues under alkaline conditions is increasingly uti-
lized for phosphorylation analysis [5–9]. The resulting
dehydroalanine/dehydrobutyric acid subsequently serves
as a Michael acceptor [5, 6]. Previous studies showed
that sulfur nucleophiles are able to form covalent thi-
oether bonds at phospho-serine/threonine residues
during Michael addition [5, 10]. Recently, Oda et al. ap-
plied a liquid-phase β-elimination-based reaction fol-
lowed by a NeutrAvidin bead purification to enrich
phospho-peptides from yeast [6]. Surprisingly, only one
phospho-peptide was obtained from this yeast phos-
pho-proteome study [6], raising a concern of feasibility
for using β-elimination/Michael addition for in vivo phos-*Correspondence: huang-chun_tseng@hms.harvard.edu (H.-C.T.);
li-huei_tsai@hms.harvard.edu (L.-H.T.)
3 Present address: Netherlands Cancer Institute, Division of Cellular
Biochemistry, 1066 CX Amsterdam, the Netherlands.pho-proteomic studies. In another study, Knight et al.
designed a phosphorylation-specific proteolysis appli-
cation using the elimination methodology to yield ly-
sine-like residues at phosphorylation sites [7]. Whether
this method is practical for complex cellular samples is
still unclear. In this report, we took advantage of the
ease of chemical diversification and the large reactive
surface area of spherical matrix (resins), routinely used
in solid-phase peptide syntheses, to design a novel ap-
proach that combines β-elimination chemistry with
solid-phase Michael addition in a convenient one-pot
procedure. Using a well-established kinase-substrate
paradigm, we show that cyclin-dependent kinase 5-phos-
phorylated Tau protein can be captured and identified
using solid-phase Michael addition from the whole-cell
system and mouse brains.
Results and Discussion
Our approach, termed solid-phase Michael addition
(SMA), for isolation of β-elimination-sensitive phospho-
peptides is illustrated in Figure 1A. Briefly, cysteine res-
idues of tryptic phospho-peptides are reduced and al-
kylated. The core chemical reactions, β-elimination and
solid-phase Michael addition, occur under alkaline re-
action conditions. Phospho-serine and -threonine are
converted to dehydroalanine and dehydrobutyric acid,
respectively. Newly formed double bonds between the
α and β carbons of dehydroalanine/dehydrobutyric acid
subsequently serve as Michael acceptors to which
nucleophilic resins react. In contrast to previously re-
ported liquid-phase Michael addition-based methods
[6–9, 11], phospho-peptides are directly captured by
the solid Michael-addition resins. Unreacted peptides
and debris are washed away while phospho-peptides
form a covalent linkage and remain on the resin. Cap-
tured peptides in tagged form are released by trifluoro-
acetic acid-mediated cleavage of the amine bond. The
chemical structure of the nucleophilic group used in the
resin is depicted in Figure 1B. The molecular mass of
the tag moiety is 203.09 Daltons (Figure 1B) and the
delta mass at serine/threonine residues is 186.12 Dal-
tons. The negatively charged phosphate is substituted
with an amide-containing tag after SMA treatment.
Phosphorylation sites on released products are subse-
quently determined by liquid chromatography-coupled
tandem mass spectrometry.
To determine whether our resin can capture phos-
phate-containing peptides, a phospho-Ser peptide de-
rived from the cyclic-AMP responding element binding
(CREB) protein was tested in the early stage of method
development. After SMA treatment, the chemically
tagged products were analyzed by matrix-assisted la-
ser desorption/absorption ionization-time of flight mass
spectrometry (MALDI-TOF MS). We found that the ma-
jor molecular ions at mass/charge (m/z) 1796.97, repre-
senting the phosphorylated form of the CREB peptide
(Figure 1C1), shifted to a higher m/z value of 1903.02
(Figure 1C2). This value matched the theoretical m/z
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770Figure 1. Scheme and Proof-of-Principle of
Solid-Phase Michael Addition Metholodogy
(A) The method involves a sample preparation
step (1. alkylation), a capturing step (2. β-elimi-
nation and 3. Michael addition), a washing
step (between 3 and 4), and a tag-releasing
step (4. acid-mediated cleavage).
(B) Detailed chemical structure of 6-(2-mer-
capto-acetylamine)-hexanoic acid RINK resin.
(C) MALDI-TOF mass spectra of 1 pmol
phospho-CREB peptides (1) before SMA
treatment and (2) after SMA treatment. Meta-
stable ions are indicated by arrowheads.value of the tagged-CREB peptide, suggesting that the (
pphosphate-containing CREB peptide was captured by
the resin and the phosphate group of the peptide was t
Preplaced with the tag moiety. A side product at m/z
2103.05 was also detected (Figure 1C2). Potential side
yreactions in SMA are discussed below. Similar CREB
peptide capture results were observed on four different u
bresin preparations. To investigate the specificity of
SMA, we attempted to isolate the phospho-CREB pep- 
Stide (1 pmol) from a nonphosphoryl peptide library with
KSYGXEXTLXAE sequences (X = any amino acids ex- r
ocept cysteine, 6859 different peptides in total, approxi-
mate weight ratio of the peptide library to the CREB f
Speptide = 8000:1). The results showed that SMA was
able to specifically capture and tag the phospho-CREB p
speptide as judged by MALDI-TOF analysis (see Figure
S1 in the Supplemental Data available with this article l
jonline). SMA did not isolate nonphosphoryl peptidesFigure S1C). In addition to phospho-Ser-containing
eptides, we found that SMA was able to capture and
ag a synthetic phospho-Thr peptide with a VDAAV(pT)-
EERH(carbamidomethyl-C) sequence (data not shown).
In addition to assessing the specificity of SMA, the
ield of capturing phospho-peptides was also eval-
ated. One nmol of CREB phospho-peptide was incu-
ated with 50 l of resin (provides approximately 10
mol of functionalized ligand). Upon treatment with
MA, all of the input peptide (1 nmol) was efficiently
ecovered (Figure S1). No phospho- and dehydro-form
f the CREB peptides were detected in the unbound
raction (Figure S1F). To test for sensitivity, 50 l of the
MA resin was incubated with various amounts of
hospho-CREB peptide. The resin was able to recover
ynthetic phospho-peptides from concentrations as
ow as 250 fmol of pure CREB phospho-peptide as
udged by MALDI-TOF measurement (data not shown).
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lic resin can specifically capture, release, and tag phos-
pho-serine/threonine-containing peptides.
To demonstrate the SMA chemistry and its applica-
tion for acquiring biological information from complex
samples, we focused on the CDK5-mediated phos-
phorylation of microtubule-associated proteins. The
longest isoform of the human microtubule-associated
protein Tau is composed of 441 amino acid residues,
among which 45 residues are serine and 35 are threo-
nine [12]. Phosphorylation events regulate the interac-
tion between Tau and microtubules [13] and facilitate
the formation of neurofibrillary tangles in Alzheimer’s
disease (AD) [14, 15]. At least 29 sites on AD-Tau are
phosphorylated by a variety of serine/threonine kinases
including PKA, GSK3β, and CDK5 [16–18]. Currently, re-
search on Tau phosphorylation is restricted to a limited
number of phosphorylation-specific antibodies, which
cannot reveal the heterogeneous phosphorylation
status of Tau. Therefore, analysis of global Tau phos-
phorylation states by improved proteomic methods is
desirable as it can contribute to a better understanding
of the mechanism underlying AD.
CDK5 is a proline-directed protein kinase essential
for development of the mammalian central nervous
system [19]. CDK5 requires association with a regula-
tory activator p35 to become active. Calpain-depen-
dent cleavage of p35 to p25 has been implicated in the
pathogenesis of AD [20]. While CDK5/p35 is a poor Tau
kinase, CDK5/p25 has been shown to cause hyper-
phosphorylation of Tau [20, 21]. 100 pmol of recombi-
nant Tau protein was phosphorylated in vitro by purified
CDK5/p25 to a stoichiometry of 0.5 phosphates per Tau
molecule. Tryptic peptides derived from the unphos-
phorylated or phosphorylated Tau protein were first an-
alyzed by MALDI-TOF MS (Figures 2A and 2B). One
peak at m/z = 1473.60 matched the mass of a mono-
phospho-peptide SGYSSPGSPGTPGSR in samples
phosphorylated by CDK5 (Figure 2B). This monophos-
pho-peptide did not appear in the control sample with-
out kinase incubation (Figure 2A). The signal intensity
of the phospho-peptide diminished after phosphatase
treatment (Figure 2C). The tryptic peptide samples con-
taining phosphorylated and dephosphorylated pep-
tides were further analyzed by SMA. One molecular ion
corresponding to the mass of SGYSSPGSPGTPGSR
plus one tag (m/z 1579.72) was observed in the phos-
phorylated sample (Figure 2D) but not in the dephos-
phorylated sample (Figure 2E). A previous report
showed that minor β-elimination may occur at serine/
threonine residues in the absence of phosphates [8].
However, we did not observe such side reactions (Fig-
ure 2E). These data suggest that SMA isolated the
phosphorylated form of the peptide, but not the un-
phosphorylated form. In addition to isolating peptides,
SMA was also tested for isolation of phospho-Tau pro-
teins. However, the method failed to isolate full-length
phospho-Tau prior to trypsin digestion, suggesting that
the solid-phase procedure is more efficient in capturing
phospho-peptides than full-length proteins.
IMAC is another method for enriching phospho-pep-
tides [22]. To compare IMAC and SMA, we used an iron
(III)-nitriloacetic acid gel (an IMAC) to enrich for the Tau
tryptic peptide pool shown in Figure 2B. A MALDI-TOFspectrum of IMAC-isolated peptides showed that IMAC
was able to isolate the same SGYSSPGSPGTPGSR
phospho-peptide isolated by SMA (Figure 2F). These
results suggest that both SMA and IMAC can enrich for
phosphorylated peptides. However, three acidic resi-
due-rich nonphospho-peptides QEFEVMEDHAGTYGL
GDR (m/z 2053.89), DQGGYTMHQDQEGDTDAGLK (m/z
2165.90), and KDQGGYTMHQDQEGDTDAGLK (m/z
2293.99) were also enriched by the IMAC approach
(Figure 2F). This may be due to the preferential enrich-
ment of acidic peptides by IMAC [4]. The overall com-
plexity of recovered peptides by SMA is less than that
obtained by IMAC. Thus, one advantage of SMA over
IMAC is that it yields less background unphosphory-
lated peptides after enrichment, increasing the prob-
ability of detecting low-abundance phosphorylation
events.
We further used tandem mass spectrometry to ana-
lyze the SMA-treated Tau peptides in order to gain se-
quence information from fragmented peptide ions. A
collision-induced dissociation spectrum obtained from
an ion-trap instrument showed a parent ion of m/z
790.35 (2+) containing the SGYSSPG (tag-S)PGTPGSR
peptide (Figure S2B). The same molecular ion was also
detected and analyzed in a quadrupole-time of flight
instrument. A quadrupole-time of flight ms/ms spec-
trum was acquired (data not shown) and the same pep-
tide sequence was detected as that detected from the
ion-trap MS spectrum. The theoretical immonium ion of
the tagged serine residue is not observed at the low
mass range, suggesting that the precursor ion scan
type of measurement may not be useful to detect phos-
pho-peptides isolated by SMA treatment. Three major
daughter ions, y4, y7, and y10, were detected in the
spectrum (Figure S2B), indicating the presence of pro-
line-induced fragmentation [23]. Background peaks or
side products shown in Figures 2D and 2E did not pro-
vide valid peptide sequence information in tandem
mass spectrometry analysis. Fragmentation of those
background peaks in MS/MS analysis did not display
a classic peptide fragmentation pattern and was not
interpreted by the MASCOT algorithm to a confident
level. The SGYSSPG (tag-S)PGTPGSR is the only valid
result, suggesting that the side products do not ad-
versely affect phosphorylation determination.
To further verify the sites on Tau phosphorylated by
CDK5, we used available phospho-Tau antibodies to
probe in vitro phosphorylated Tau. AT-8 antibody, raised
against phospho-S202/T205 of Tau [24], recognized in
vitro CDK5-phosphorylated Tau (Figure S2A). Con-
versely, T231 of Tau is not an ideal substrate for CDK5
[18], and neither SMA nor the phosphorylation-specific
antibody pT231 (Figure S2A) detected the phosphoryla-
tion of this residue by CDK5. Thus, these phospho-epi-
tope-specific antibodies confirm the SMA-determined
phosphorylation status of Tau.
To study Tau phosphorylation in a more biologically
relevant context, we transfected human Tau with or
without the active CDK5 complex in neuroblastoma
CAD cells. Heat-stable protein samples (250 g) pre-
pared from transfected cells were treated with SMA fol-
lowed by tandem mass spectrometric analysis. Results
showed that residues T169, T181, S185, S191, S195,
S198, S199, S202, T205, S208, S210, T217, T220, S241,
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772Figure 2. MALDI-TOF Mass Spectrometric
Analysis of Phosphorylated Tau
Recombinant Tau (100 pmol) was phosphor-
ylated by active CDK5 in vitro. Tryptic Tau
peptides prepared from samples in the ab-
sence and presence of active CDK5 are
shown in (A) and (B), respectively. As a con-
trol, CDK5-phosphorylated peptides were
treated with alkaline phosphatases. The MS
spectrum of dephosphorylated peptides is
shown in (C). After a peptide mass finger-
print analysis, one phospho-peptide, SGY
SSPGSPGTPGSR, plus 1 phosphate was de-
tected and is indicated by an arrow. The
non-phospho-peptide counterpart is indi-
cated by an arrowhead. The phosphorylated
and dephosphorylated samples were pre-
pared by SMA prior to MS analysis ([D] and
[E], respectively). The peptide with the tag,
representing the phospho-peptide, is de-
tected in spectrum (D), but not in (E). The
phospho-peptide was also isolated by using
IMAC, another technique for enriching phos-
pho-peptides (F).S396, and T403 were phosphorylated (Figure 3B, Table a
yS1). Among these residues, T181, S199, S202, T205,
T217, and S396 are (S/T)P sites representing the CDK5-
(phosphorylation motif and were previously reported
CDK5 sites [18, 25–29]. Immunoblots using phospho- a
CTau antibodies showed that phosphorylation of S202,
T205, and S396 was significantly increased, whereas p
ono phosphorylation of T231 was detected in the sample
prepared from CDK5/p25/Tau triple transfected CAD t
mcells (Figure 3A), supporting results obtained by SMA
followed by mass spectrometry (Table S1). Most phos- T
apho-Tau peptides listed in Table S1 were not detected
in the PKA-Tau-transfected controls (phosphorylation j
ocontrol) or in an unfunctionalized resin control (nonspe-
cific binding control) (data not shown). We previously w
treported the phosphorylation of endogenous Tau in the
brain of a p25-overexpressing mouse model using con- A
fventional tandem mass spectrometry [30]. Here, we
found extensive overlap of phosphorylation sites de- o
ptected in the animal model and the cell-based system,
including S195, S198, S199, S202, T205, S217, T220, t
S396, and T403. Phosphorylation at S185, S191, S208,nd S210 discovered in this report are novel phosphor-
lation sites.
The detection of non-(S/T)P phosphorylation sites
T169, S185, S191, S195, S198, S208, S210, T220, S241,
nd S403 in Figure 3B) that do not correspond to the
DK5 phosphorylation motif suggests that overex-
ressed Tau in CAD cells is also phosphorylated by
ther Ser/Thr kinases. Some peptides were multiply
agged (Table S1), suggesting that the resin can label
ultiple phosphorylation sites on the same peptide.
he presence of disulfide-linked tag dimers after the
cid cleavage suggests that the spatial proximity of ad-
acent ligands allows the reactions of multiple tags on
ne peptide to occur. We note that not all phosphates
ere replaced by the chemical tag. That may be due
o the alkaline strength of SMA β-elimination condition.
nother speculation suggests that β-elimination is in-
luenced by the sequence, composition, and structure
f peptides. Nevertheless, both the tagged and phos-
horylated forms of serine and threonine can be simul-
aneously identified by tandem mass spectrometry.
In addition to phospho-Tau peptides, we also de-
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773Figure 3. Detection of Tau and MAP2 Phos-
phorylation in a Whole-Cell System
(A) Immunoblotting assay of Tau proteins.
Tau-5 is an antibody recognizing total Tau.
AT-8 antibody recognizes phosphorylation of
S202/T205 of Tau. PHF-1 specifically recog-
nizes phospho-S396. pThr231 antibody rec-
ognizes phosphorylation of T213 at Tau.
(B) Comparison of CDK5-mediated phos-
phorylation of MAP2 and Tau in CAD cells.
Partial sequences of MAP2 (NCBI access
number NP_002365) and Tau (access num-
ber QRHUT1) are shown. Pairwise alignment
of MAP2 and Tau was done with the BioEdit
software using the PAM120 algorithm. Black
blocks indicate identical amino acids; gray
blocks indicate amino acids with similar
chemical and physical properties. Dashes
represent probable gaps. Phosphorylation
sites detected in CDK5-active cells were la-
beled with stars. Note that most of the sim-
ilar phosphorylation sites of the two proteins
appear in the highly homologous regions.tected phospho-peptides derived from other cellular
proteins in CAD cells. Among these proteins, we dis-
covered a phosphopeptide corresponding to microtu-
bule-associated protein 2 (MAP2), a potentially novel
CDK5 substrate. We decided to focus on MAP2 be-
cause it shares nearly identical microtubule binding re-
peats and a proline-rich region [31] with Tau. Like Tau,
MAP2 is also phosphorylated by multiple kinases [32].
However, information on the specific phosphorylation
sites are limited and it is not known whether CDK5
phosphorylates MAP2 in cells [32]. Using SMA, we
found that endogenous MAP2 was phosphorylated in
cells transfected with Tau alone (Table S1). This sup-
ports a previous study that MAP2 is constitutively
phosphorylated in vivo [33]. In the control sample,
phosphorylation at residues T1452, T1507, S1514,
S1519, S1528, and S1555 was detected (Table S1). In
CDK5-active cells, residues S1528, S1534, S1555,
T1613, T1616, T1619, S1621, and S1782 were phos-
phorylated (Table S1). Interestingly, in CDK5/p25-express-
ing cells, specific phosphorylation of MAP2 was limited
to (S/T)P sites (S1534, T1613, T1616, T1619, and S1782
in Table S1), whereas phosphorylation events at S1528
and S1555 appeared in both control and CDK5-acti-
vated cells. Among these (S/T)P phosphorylation sites,
T1613/T1616/T1619 and S1782 on MAP2 are at analo-
gous regions of S199/S202/T205 and S396 on Tau, the
two main CDK5 phosphorylation modules of Tau (Figure
3B). The sequence 1613TPGTPGTP1620 is located in
the proline-rich region of MAP2, and phosphorylation
of this proline-rich region was observed in growth re-
gions of rat hippocampal neurons [34]. In an in vitro
phosphorylation experiment, purified CDK5/p25 was
able to phosphorylate (S/T)PG(S/T)PGTP peptides and
purified MAP2 (data not shown). Thus, with the use of
SMA, we were able to identify a novel CDK5 substrate
that was further confirmed by in vitro phosphorylation.Previous studies showed that CDK5 preferably phos-
phorylates the (S/T)PX(K/H/R) sequences [35]. Our re-
sults suggest that 1613TPGTPGTP1620 of MAP2 and
199SPGSPGTP206 of Tau may represent another CDK5
phosphorylation motif, (S/T)PG(S/T)PGTP. Furthermore,
this motif features two consecutive PXXP sequences
known to be SH3 domain binding sites [36, 37]. Phos-
phorylation of this motif influences binding of the SH3
domain of the protein tyrosine kinase Fyn to Tau [38]
and binding of the prolyl isomerase Pin1 to Tau [39].
The binding of Src to MAP2 is inhibited by phosphory-
lation of MAP2 by MAPK and ERK2, but not by PKA
[37]. It is tempting to speculate that CDK5 phosphoryla-
tion of this motif on MAP2 may have similar effects as
that observed on Tau. However, additional evidence for
direct regulation of MAP2 by CDK5 is necessary to test
this hypothesis.
To understand the basal phosphorylation status of
the heat-stable proteins in vivo, we treated 250 g of
tryptic peptides derived from the heat-stable fraction
of mouse forebrains with SMA. We detected a total of
205 peptides from 999 MS/MS spectra. Among those
peptides, there are 105 phospho-peptides and 184
phosphorylation sites (Table S2). The majority of recov-
ered phospho-peptides were mono-phospho-peptides
(41%) and di-phospho-peptides (46%). Tri-phospho-
peptides and quadru-phospho-peptides encompass
only 12% of the total phospho-peptides. One peptide
derived from Tau, 526SPSASKSR533 (numbering based
on 732 amino acid-long Tau) was tagged at residues
S526 and S532 (or S235 and S241 on 441 amino acid-
long Tau in Figure 3). The phosphorylation sites on the
MAP2 peptide, 1650TPPKSPATPK1659 (Table S2), cor-
respond to phosphorylation of T1649, S1653, and
T1656 in human MAP2 (Figure 3).
In summary, a plethora of techniques have been de-
veloped to aid in mass spectrometry-based phospho-
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774proteomic analysis, including phospho-specific anti- p
bodies, affinity chromatography, chemical modification, i
precursor ion scanning, neutral-loss scanning, and m
electron capture dissociation techniques [4, 7, 40]. The f
feasibility of β-elimination/Michael addition for phos- p
pho-peptide analysis was raised by a previous report 3
[6]. Here we present evidence that our novel solid- m
phase procedure is able to efficiently isolate and iden- C
tify phospho-peptides from whole-cell systems. There p
are several notable discrepancies between our and pre- a
viously published procedures. First, the labeling of c
phosphorylation sites and enrichment of phospho-pep- a
tides by our method occurs in a single solid-phase one- l
pot reaction, which may reduce the likelihood of sam- o
ple loss. This one-pot reaction is different from previous e
attempts that perform β-elimination and Michael addi- p
tion in the liquid phase, followed by a separate solid- g
phase extraction to recover peptides [6, 8, 9] Second, c
the mass of the 6-(2-mercapto-acetylamine)-hexanoic r
amide tag, which is smaller than a previously described r
biotin tag [6], allows for a wider detection window in c
the mass spectrometric measurement. Third, a previ- r
ous study reports that replacement of a phosphate with t
an amine-containing moiety at phosphorylation sites h
can enhance phospho-peptide detection in mass spec- A
trometry [7]. We failed to detect neutral-loss of the 6-(2- a
mercapto-acetylamine)-hexanoic amide tag by MALDI-
TOF MS analysis (Figures 1C2 and 2D) or by tandem
Smass spectrometric analysis (data not shown), sug-
gesting that the tag is a more stable moiety than a
Wphosphate. Fourth, we use barium hydroxide, which is
tmore efficient than sodium hydroxide or potassium hy-
odroxide reported previously, to catalyze β-elimination
d[8, 41]. β-elimination may also occur on carbamido-
lmethylated cysteinyl or O-linked glycosylated peptides
o[41]. In our hands, carbamidomethyl cysteinyl residues
wremain intact and do not undergo β-elimination. The
suse of barium hydroxide can significantly reduce the
treaction rate of β-elimination of O-linked glycosylated
speptides by two orders of magnitude compared to that
rof phospho-Ser/Thr peptides [41]. Thus, these potential
aside reactions should be very minor during SMA. Fifth,
ca minor side product 200.05 Daltons heavier than the
Ttagged peptide is observed and forms an ion pair with
ithe tagged peptide (Figure 1C2). We tested for occur-
Srences of various potential side reactions, including io-
pdination on tyrosine residue, oxidation on the sulfur of
sthe SMA ligand and cysteine residues, dehydration of
unphosphorylated serine/threonine residues, and unex-
pected acid cleavage sites on the RINK resin. However, E
none of these possibilities accounted for the minor side
Mreaction observed during the SMA reaction. The side
Rproduct cannot be explained by an additional tag
n
added to unphosphorylated serine/threonine residues t
because the delta mass of an additional tag is 186.12 (
Daltons. Nevertheless, this side reaction does not have f
any adverse effects on data analysis. Dephosphoryla- S
ltion of phospho-peptides with phosphatases prior to
wSMA may serve as an additional control to ensure accu-
Mrate phosphorylation determination.
a
Recently, Collins et al. showed that different IMAC M
protocols yield different coverage in phosphorylation w
site determination [42]. Our preliminary phospho-pro- f
fteomic studies on mouse brains suggest that phospho-eptides recovered by SMA and IMAC are not entirely
dentical (unpublished result). It is likely that different
ethods of capturing phospho-peptides enrich dif-
erent groups of phospho-peptides. A study of phos-
horylation events on synaptic proteins showed that
51 phospho-peptides were recovered from approxi-
ately 18 mg of sample by IMAC approaches [42].
lassic IMAC and improved IMAC [40] likely isolate
eptides with multiple phosphorylation sites [42]. The
pplication of strong cation exchange chromatography
ombined with neutral-loss detection of phosphoric
cid allowed detection of more than 2,000 phosphory-
ation sites among 525,000 MS/MS spectra when 8 mg
f starting materials was used [43]. This strong cation
xchange method prefers the isolation of monophos-
ho-peptides [42]. In contrast, SMA is designed to tar-
et β-elimination-sensitive phosphorylation sites. The
ovalent bond linkage of the phospho-peptide to SMA
esins is more stable during the non-phospho-peptide
emoval step than the ionic linkage in IMAC or strong
ation exchange. SMA is expected to recover a wide
ange and yield a higher percentage of phospho-pep-
ides. The phospho-proteomic analysis of mouse brain
eat-stable proteins (Table S2) supports this notion.
dditional analyses using whole cell or tissue samples
re necessary to further examine the efficiency of SMA.
ignificance
e present the first evidence for successful applica-
ion of solid-phase Michael addition for the purpose
f phospho-peptide enrichment. This report not only
emonstrates mass spectrometry-based phosphory-
ation determination, but also extends the application
f solid-phase chemistry to tag biological samples
ith phosphorylation modifications. The newly de-
igned thio-nucleophilic resin fulfills two functions,
he capturing and tagging of phospho-peptides in one
ingle reaction vessel when -elimination and Michael
eaction occur. Solid-phase chemistry is convention-
lly applied to small molecule synthesis, chemical
apturing, peptide synthesis, and reaction catalysis.
his SMA application extends the solid-phase chem-
stry to labeling purposes. Furthermore, the novel
MA method will improve current detection of Ser/Thr
hosphorylation reactions and broaden the under-
tandings of biological processes and diseases.
xperimental Procedures
aterials
INK resin (ArgoGel-RINK-NH-Fmoc) was purchased from Argo-
aut Technologies (San Carlos, CA). PyBOP (benzotriazole-1-yl-oxy-
ris-pyrrolidino-phosphonium hexafluorophosphate) and SAMA-OPfp
S-acetylthioglycolic acid pentafluorophenyl ester) were purchased
rom Calbiochem-Novabiochem AG (Laufelfingen, Switzerland).
ynthetic phospho-Ser CREB peptide was obtained from New Eng-
and Biolabs. Phospho-Thr VDAAV(phospho-T)TEERHC peptide
as synthesized at Tufts Core Facility, Tufts University (Medford,
A). Phos-Select iron affinity gel, an iron(III)-nitriloacetic acid gel,
nd MAP2 protein were obtained from Sigma-Aldrich (St. Louis,
O). Tau-5 (monoclonal) and Tau [pThr231] (polyclonal) antibodies
ere purchased from Biosource (Camarillo, CA); AT-8 (monoclonal)
rom Innogentics (Belgium). PHF-1 (monoclonal) antibody is a gift
rom M.D. Nguyen (Harvard Medical School). Horseradish peroxi-
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775dase (HRP)-conjugated AntiMouse/AntiRabbit IgG secondary anti-
bodies were purchased from Amersham Biosciences (Piscataway,
NJ). Chemiluminescence reagents used in immunoblotting assay
were purchased from NEN Life Science Products (Boston, MA). All
other compounds are reagent grade. The DNA constructs hTau40,
CDK5-HA, and p25-HA were described previously [21]. Active
CDK5/p25 complex was provided by Andrea Musacchio at Euro-
pean Institute of Oncology (Italy).
Synthesis of Nucleophilic RINK Resin
Synthesis of the resin is based on Fmoc chemistry to add the
6-(mercapto-acetylamino)-hexanoic acid group onto ArgoGel
RINK-NH-Fmoc resin (approximate ligand stoichiometry, 0.3 mmol/
gram of resin). Solid-phase peptide synthesis was carried out on
an 180° Variable Rate Shaker (Peptides International, Louisville,
KY). 2.5 grams (dry weight) of ArgoGel RINK-NH-Fmoc resin were
first swelled in 20 ml of DMF solvent for 10 min at room tem-
perature and then incubated in 50 ml of 20% piperidine/DMF solu-
tion for 1 hr at room temperature in order to remove the Fmoc
group. After Fmoc removal, resins were washed extensively in DMF
(N, N-dimethylformamide, American Bioanalytical, Natick, MA).
Fmoc--Ahx-OH (N-fluorenyl oxycarbonyl hexanoic acid, 5 equiva-
lents to the number of RINK-NH-Fmoc moles on the resins) was
preactivated with PyBOP (6 equivalents to the number of Fmoc--
Ahx-OH moles) and DIPEA (di-isopropylethylamine, 6 equivalents
to the number of Fmoc--Ahx-OH moles) in DMF for 2 min and
added to the resin. After 30 min, the resin was washed extensively
and followed by a second coupling overnight. A standard Fmoc
removal procedure of the protective group was applied to remove
the terminal Fmoc group. SAMA-OPfp (5 equivalents to the number
of RINK-NH-Fmoc moles) was added in DMF and the resin was
incubated for 30 min followed by a second coupling overnight. The
terminal acetyl group on the ligand, which prevents the thiol group
from oxidation during storage, was removed before use of the resin
in DMF containing 10% ammonium hydroxide for 1 hr followed by
extensive washing with DMF (3 times), ethanol (3 times), and water
(3 times). Completion of each coupling step was monitored by the
Kaiser test that detected free terminal amino groups in solid-phase
synthesis of peptides [44]. Because of the absence of free amino
groups after each synthesis step, all RINK-NH-Fmoc ligand are
converted. An LCT LC-MS instrument (Waters, Milford, MA) was
used to monitor the synthesis of the resin by analyzing acid-
cleaved products.
-Elimination and Solid-Phase Michael Addition
One-pot β-elimination and Michael addition reactions were ef-
fected in 10% acetonitrile and 20 mM Ba(OH)2 (pH 10.5) in closed
microcentrifuge tubes at 37°C under gentle agitation for 16 hr.
Freshly prepared 2-mercaptoacetyl-hexanoyl functionalized beads
(30 l of bed volume) were used in a reaction with 1 pmol of syn-
thetic polypeptides or with 500 g of cellular polypeptides. Unfunc-
tionalized RINK resin was used in parallel as a control to examine
nonspecific binding. Reactions were terminated by adjusting the
pH to 5 with acetic acid. Reaction solutions were removed and the
resins were collected after brief centrifugation. Resins were subse-
quently washed in sequence with PBS (phosphate-buffered saline),
50% methanol, 90% acetonitrile, 100% DMF, and 100% methanol,
with two washes in each solvent for 5 min. Resins were dried in
a SpeedVac. Peptide cleavage was carried out by two steps of
incubating 200 l of 20% TFA (trifluoroacetic acid in water) to the
resins at room temperature for 30 min each. A total of 400 l of
cleavage products was collected and the volume was reduced to
100 l in a SpeedVac. Peptides in the TFA solution were precipi-
tated in 1 ml of cold diethyl ether and collected after centrifugation
at 15,000 × g for 10 min. The isolated peptides were dried in a
SpeedVac and used for mass spectrometric analysis.
Cell Culture and DNA Transfection
Human neuroblastoma CAD cells were cultured in DMEM contain-
ing 10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml peni-
cillin, and 100 g/ml streptomycin at 5% CO2, 37°C. At 80%–90%
confluence, cells were transferred to Opti-MEM media containing
glutamine for transfections. Transfections were performed with Li-pofectamine 2000 following the vender’s protocol (Invitrogen,
Carlsbad, CA). 20 g of Tau contruct, 20 g of CDK5 construct,
and 20 g of p25 construct were used for transfection of cells in
one 150 cm2 flask. 24 hr posttransfection, Opti-MEM medium was
removed and cells were washed with cold PBS. To generate protein
kinase A-Tau, CAD cells were transfected with Tau constructs for
24 hr followed by a 1 hr treatment with 10 M foskolin (Sigma-
Aldrich).
Preparation of Heat-Stable Protein Samples
and Immunoblotting Assay
Transfected cells (2–4 × 107 cells) or mouse forebrain tissues (0.1–
0.25 g) were homogenized and lysed in cold RIPA buffer (150 mM
NaCl, 1% NP-40, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1%
SDS, 50 mM Tris [pH 8.0]) containing 1 mM DTT, 1 mM NaF, 1 mM
Na3VO4, 10 nM calyculin-A, 100 nM cyclosporine A. Cell lysates
were collected after short centrifugation to remove cell debris. Tau
and MAP2 are heat-stable proteins that can be enriched by heat
treatment [15]. Cell lysates were heated at 90°C for 5 min. Heat-
stable protein lysates were collected by a 15,000 × g centrifugation
for 10 min at 4°C. For immunoblotting, 1 g of each protein sample
was resolved on a 12% SDS-PAGE gel. Proteins were electro-trans-
ferred onto PVDF membranes. Tau-5 (1:500 dilution), AT-8 (1:1000),
PHF-1 (1:500), and Tau[pS396] (0.5 g/ml) were used for the pri-
mary antibody binding reaction. HRP-conjugated anti-mouse anti-
body (1:5000) or HRP-conjugated anti-rabbit antibody (1:5000) was
used in secondary antibody binding. The labeled Tau proteins were
visualized by chemiluminescence and film exposure.
Preparation of Peptides and IMAC Sample
Phospho-Thr VDAAV(phospho-T)PEERHC peptides (1 mg/ml) were
incubated with iodoacetamide (10 mg/ml) for 30 min at room tem-
perature in dark. The carbamodimethylation was quenched by ad-
dition of 8 mM DTT. Recombinant Tau was prepared as described
previously [13]. The in vitro phosphorylation conditions of Tau
(1 g) was previously described [13], except that 50 ng of purified
CDK5/p25 was used instead. The in vitro phosphorylation of MAP2
used the same condition as that of Tau. Phosphorylated Tau was
digested with trypsin at a ratio of 100:1 (w/w) at 37°C overnight.
Phosphorylation was stopped by adding acetic acid when Tau was
phosphorylated to 0.4–0.5 phosphates per Tau molecule. Dephos-
phorylation of CDK5-Tau peptides was performed with 5 units of
alkaline phosphatase at 37°C for 4 hr. The IMAC procedure in this
study followed the vender instructions. Phos-Select iron affinity gel
(100 l) was incubated with Tau phospho-peptides. The binding
condition of Tau peptides and IMAC resin was 250 mM acetic acid
in 25% acetonitrile. Bound peptides were eluted in 150 mM ammo-
nuion hydroxide in 25% acetonitrile. In microtubule-associated pro-
tein experiments, 250 g of heat-stable proteins were treated with
sequencing-grade trypsin at a ratio of 50:1 (proteins: trypsin) in 50
mM ammonium bicarbonate at 37°C for 16 hr. All peptides (syn-
thetic and expressed) were transferred to PlusOne Mini dialysis
bags with 1 kDa cut-off (Amersham Bioscience) and dialyzed
against water at 4°C overnight. A C18 reverse phase chromatogra-
phy may be used to substitute the dialysis step. Lyophilized pep-
tides were stored at −20°C for the subsequent capture-release-tag
procedure and mass spectrometry.
Mass Spectrometry
MALDI-TOF mass spectrometric analysis of synthetic peptides was
performed in a Voyager DE-STR MALDI-TOF mass spectrometer
(Applied Biosystems, Foster City, CA) in the positive ion, delayed-
extraction, and reflector-on mode. General settings of the MALDI-
TOF experiments were as follows: accelerating voltage 20,000 V,
grid voltage 75%, guide wire 0.02%, extraction delay time 200 ns.
Peptide samples were desalted with ZipTip C18 preloaded tips
(Millipore, Bedford, MA). Bound peptides were eluted from the tips
with 2 l of a solution containing 10 mg/ml α-cyano-4-hydroxycin-
namic acid, 50% actetonitril, 10% ethanol, and 0.1% TFA solution
and spotted directly onto a gold-coated target plate. For the analy-
sis of microtubule-associated proteins, a Micro Q-TOF system was
used (Waters, Milford, MA). The system includes a HPLC liquid
chromatography (CapLC) online-coupled with a nano-electrospray
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776ionization quadrupole-time of flight instrument. Cleaved products
derived from a starting material of 500 g peptide samples (Tau,
CDK5-Tau, and PKA-Tau) or 250 g heat-stable samples were in-
jected into the HPLC system equipped with a PicoFrit C18 column
(New Objective, Woburn, MA). Mixtures of peptides were resolved
in a 90 min gradient (5%–40% of acetonitrile) with a flow rate of 0.8
l/min. The top three strongest ion peaks in parent-ion-scan mode
(m/z 400–2000, 1 s/scan) were automatically selected for subse-
quent CID analysis (m/z 90–2000, 1.5 s/scan). Collision energy in
CID analysis used a default mass-charge-dependent profile pro-
vided by the vender. TFA-cleaved tagged peptides, which were de-
rived from a starting material of 10 g peptides, were also analyzed
with the same system. Mixtures of peptides were resolved in a 120
min gradient (5%–40% of acetonitrile) with a flow rate of 0.8 l/
min. Collision energy in CID used a default mass-charge-depen-
dent profile provided by the vender. The ion-trap tandem mass
spectrometry was carried out at NanoApplication Scientific (Med-
ford, MA). The mass spectrometer LCQ Deca XP was coupled to
a micro-spray Vydac C18 column HPLC system and operated by
Xcalibur 1.2 XP1 software.
Analysis of Mass Spectrometric Data
1Raw data obtained from Q-TOF tandem mass spectrometric analy-
sis was processed with MassLynx 4.0 software (Waters, Milford,
MA) to generate peak lists. Raw data acquired from ion-trap tan-
dem mass spectrometric analysis was processed with Biowork 3.1
1software (Thermo Electron, CA) to generate peak lists. Peak lists of
each sample were submitted to a Mascot server (Matrixscience,
London, UK) and searched against the SwissProt protein database.
Unmatched peak lists were further submitted to the Mascot server
1against a customized MAP-Tau database. Tolerance of parent ions
and daughter ions were 1.5 and 0.6 Daltons, respectively. Minimal
Mascot score was set to 26 for the first data filtration. All Mascot
results were also crossexamined with their corresponding CID 1
spectra manually to ensure fidelity of the computational outcome.
1
Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.chembiol.com/cgi/
content/full/12/7/769/DC1/. 1
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